Catalent, Inc. (NYSE:CTLT – Get Rating) SVP Kay A. Schmidt sold 323 shares of Catalent stock in a transaction dated Tuesday, July 26th. The shares were sold at an average price of $106.90, for a total value of $34,528.70. Following the completion of the transaction, the senior vice president now directly owns 13,455 shares of the company’s stock, valued at $1,438,339.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Catalent Price Performance
Catalent stock opened at $113.10 on Friday. The firm has a market capitalization of $20.27 billion, a P/E ratio of 40.98, a PEG ratio of 1.64 and a beta of 1.32. Catalent, Inc. has a 1 year low of $86.34 and a 1 year high of $142.64. The business has a 50-day moving average of $106.25 and a 200-day moving average of $102.89. The company has a current ratio of 2.89, a quick ratio of 2.25 and a debt-to-equity ratio of 0.90.
Catalent (NYSE:CTLT – Get Rating) last posted its earnings results on Tuesday, May 3rd. The company reported $1.00 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.89 by $0.11. The company had revenue of $1.27 billion during the quarter, compared to analyst estimates of $1.22 billion. Catalent had a return on equity of 15.07% and a net margin of 10.72%. The company’s revenue for the quarter was up 20.9% compared to the same quarter last year. During the same period in the previous year, the company earned $0.78 EPS. On average, equities analysts anticipate that Catalent, Inc. will post 3.57 EPS for the current year.
Hedge Funds Weigh In On Catalent
Institutional investors have recently modified their holdings of the stock. Parkside Financial Bank & Trust grew its position in shares of Catalent by 127.4% during the 4th quarter. Parkside Financial Bank & Trust now owns 282 shares of the company’s stock worth $36,000 after buying an additional 158 shares during the period. Prospera Financial Services Inc bought a new position in shares of Catalent during the 1st quarter valued at about $33,000. Covestor Ltd bought a new position in shares of Catalent during the 4th quarter valued at about $39,000. Ellevest Inc. lifted its holdings in shares of Catalent by 39.5% during the 1st quarter. Ellevest Inc. now owns 406 shares of the company’s stock valued at $45,000 after purchasing an additional 115 shares in the last quarter. Finally, Sageworth Trust Co of South Dakota bought a new position in shares of Catalent during the 4th quarter valued at about $63,000. 98.05% of the stock is currently owned by institutional investors and hedge funds.
Analysts Set New Price Targets
Separately, Deutsche Bank Aktiengesellschaft lowered their price objective on Catalent from $129.00 to $110.00 and set a “hold” rating for the company in a research report on Tuesday, April 12th. Two equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to MarketBeat.com, Catalent presently has a consensus rating of “Moderate Buy” and a consensus price target of $142.86.
Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates through four segments: Biologics, Softgel and Oral Technologies, Oral and Specialty Delivery, and Clinical Supply Services.
Receive News & Ratings for Catalent Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Catalent and related companies with MarketBeat.com’s FREE daily email newsletter.